



RECEIVED
AUG 07 2001
TECH CENTER 1600/1900
(Form PTO-1449)
Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 7979	APPLICATION NO.: 09/835,196
	INVENTOR: Barnett S. Pitzele, et al.	
	Filed: 4/13/01	Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
PM	C1	S. Moncada and E. Higgs, <i>Molecular Mechanisms and Therapeutic Strategies Related to Nitric Oxide</i> 1995, FASEB J., 9, 1319-1330
	C2	S. Rozen, I. Shahak, and E. Bergmann, <i>Organic Fluorine Compounds Part XLIV. Preparation and Reactions of Epifluorohydrin</i> 1971, Synthesis 646-7
	C3	E. Bergmann, S. Cohen, and I. Shahak, <i>Organic Fluorine Compounds. Part XX. Some Reactions of 1-Chloro-3-fluoropropan-2-ol and Epifluorohydrin</i> 1961, J Chem Soc 3448-52
	C4	A. Jeanguenat and D. Seebach, <i>Stereoselective Chain Elongation at C-3 of Cysteine through 2,3-Dihydrothiazoles, Without Racemization. Preparation of 2-Amino-5-hydroxy-3-mercapto alkanolic Acid Derivatives.</i> 1991, J. Chem. Soc. Perkin Trans. 1, 2291-8
	C5	G. Pattenden, S. Thom, and M. Jones, <i>Enantioselective Synthesis of 2-Alkyl Substituted Cysteines.</i> 1993, Tetrahedron, 49, 2131
	C6	D. Bredt and S. Snyder, <i>Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme.</i> 1990 <u>Proc. Natl. Acad. Sci. U.S.A.</u> , 87, 682-685
	C7	Moore et al, <i>2-Iminopiperidine and Other 2-Iminoazaheterocycles as Potent Inhibitors of Human Nitric Oxide Synthase Isoforms</i> 1996 <u>J. Med. Chem.</u> , 39, 669-672
	C8	T. Misko et al, <i>A Fluorometric Assay for the Measurement of Nitrite in Biological Samples</i> 1993, <u>Analytical Biochemistry</u> , 214, 11-16
	C9	Y. Lee et al., <i>Conformationally-restricted Arginine Analogues as Alternative Substrates and Inhibitors of Nitric Oxide Synthases</i> 1999 <u>Bioorg. Med. Chem.</u> 7 1097-1104
PM	C10	R. Young et al., <i>Inhibition of Inducible Nitric Oxide Synthase by Acetamidine Derivatives of Hetero-Substituted Lysine and Homolysine</i> 2000 <u>Bioorg. Med. Chem. Lett.</u> 10 597-600

EXAMINER 	DATE CONSIDERED 6.1.02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)



RECEIVED
 AUG 07 2001
 TECH CENTER
 Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">ATTY. DOCKET NO.: 7979</td> <td style="width: 50%;">APPLICATION NO. 09/835,196</td> </tr> <tr> <td colspan="2">INVENTOR: Barnett S. Pitzele, et al.</td> </tr> <tr> <td>Filed: 4/13/01</td> <td>Group: 1614</td> </tr> </table>	ATTY. DOCKET NO.: 7979	APPLICATION NO. 09/835,196	INVENTOR: Barnett S. Pitzele, et al.		Filed: 4/13/01	Group: 1614
ATTY. DOCKET NO.: 7979	APPLICATION NO. 09/835,196						
INVENTOR: Barnett S. Pitzele, et al.							
Filed: 4/13/01	Group: 1614						

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PAC	A1	5 1 3 2 4 5 3	7/21/92	Griffith	562	560	3/23/91
	A2	5 6 8 4 0 0 8	11/4/97	Hallinan et al.	514	256	11/9/94
	A3	5 8 3 0 9 1 7	11/3/98	Moore et al.	514	634	9/11/95
	A4	5 8 5 4 2 5 1	12/29/98	Hallinan et al.	514	256	4/30/97
	A5	5 8 6 3 9 3 1	1/26/99	Beams et al.	514	357	6/22/94
	A6	5 9 1 9 7 8 7	7/6/99	Hallinan et al.	514	256	10/5/98
	A7	5 9 4 5 4 0 8	8/31/99	Webber et al.	514	63	8/8/96
	A8	5 9 8 1 5 1 1	11/9/99	Gapud et al.	514	63	3/5/97
	A9	5 9 9 4 3 9 1	11/30/99	Lee et al.	514	431	7/2/98
PAC	A10	6 1 6 9 0 8 9	1/2/2001	Hallinan et al.	514	256	3/12/99

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
PAC	B1	WO 93 1 3 0 5 5	7/8/93	International	C07C	257/14	X	
	B2	WO 93 1 6 0 5 5	8/19/93	International	C07D	281/10	X	
	B3	WO 94 1 2 1 6 5	6/9/94	International	A61K	31/155	X	
	B4	WO 94 1 4 7 8 0	7/7/94	International	C07D	239/48	X	
	B5	WO 95 1 1 0 1 4	4/27/95	International	A61K	31/00	X	
	B6	WO 95 1 1 2 3 1	4/27/95	International	C07D	207/22	X	
	B7	WO 95 2 5 3 8 2	9/21/95	International	H03H	17/02	X	
	B8	WO 95 2 5 7 1 7	9/28/95	International	C07C	257/14	X	
	B9	WO 96 1 5 1 2 0	5/23/96	International	C07D	257/06	X	
	B10	WO 96 3 5 6 7 7	11/14/96	International	C07D	223/12	X	
	B11	WO 96 3 3 1 7 5	10/24/96	International	C07D	223/12	X	
	B12	WO 97 0 6 8 0 2	2/27/97	International	A61K	31/495	X	
	B13	WO 99 2 9 8 6 5	6/17/99	International	C12N	15/28	X	
	B14	WO 99 4 6 2 4 0	9/16/99	International	C07C	257/14	X	
PAC	B15	EP 05 2 1 4 7 1	10/25/00	European	C07D	239/42	X	
	B16	EP 04 4 6 6 9 9	5/31/00	European	C07K	5/06		

EXAMINER 	DATE CONSIDERED 7.1.02
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	